Polpharma Biologics is a fully integrated biopharmaceutical CDMO – offering the complete spectrum of services from cell line generation to drug substance and drug product development and manufacturing.
As a division of one of the largest pharmaceutical companies in Central Europe, we are building on the extensive quality standards and track record of Polpharma Group. By continuously investing in state-of-the-art infrastructure and personnel, we achieve and maintain the highest level of quality while securing competitive prices for our customers.
Our offerings are tailor-made for companies around the world seeking to develop either innovative biologics or biosimilars.
Flexibility and speed are integral components of our modular one-stop-shop. We provide our clients with what they need, when they need it.
- Utrecht, Netherlands
Cell Line Development
Center of excellence for the development of mammalian cell lines for monoclonal antibodies (MAbs) and other therapeutic proteins with a strong focus on CQA modulation and titer optimization.
- Gdańsk, Poland
Development & GMP Manufacturing
Our integrated biopharmaceutical development and GMP drug substance manufacturing facility in Gdańsk is one of the most modern in Europe, employing both microbial and mammalian systems, as well as aseptic fill & finish of final drug product. We use high-throughput process development technologies and modular, single-use cGMP manufacturing.
- Duchnice, Poland
Commercial Drug Substance Manufacturing & Aseptic Fill & Finish
To secure supply of commercial quantities for global demand, we are building a new modular cGMP facility in Duchnice, near Warsaw, which will house mammalian drug substance manufacturing and aseptic fill & finish.
At Polpharma Biologics, we are eager to support your next biopharmaceutical project with our integrated development and large-scale production capabilities.